Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Adenovirus Type 5 Injection with PD-1 Antibody in Advanced Melanoma
NCT05928962Phase 1Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Oncorine in Malignant Melanoma (MM), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
Oncorine
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT05928962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928962.